CClinicalTrials.gg
CompletedNCT00269373Updated Feb 22, 2012

Positron Emission Tomography - Computed Tomography (PET-CT) Scan as a Diagnostic Method in Unknown Primary Tumors

An observational study in Unknown Primary Tumor, sponsored by Rigshospitalet, Denmark. Completed at 1 site in Denmark. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-02-22.

Sponsored by Rigshospitalet, Denmark · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
136
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Is PET-CT scan better than PET or CT alone in diagnosing primary tumours in patients with unknown primary tumors? Can information obtained with PET-CT replace other clinical and radiological investigations? Is PET/CT cost-effective?

Read the detailed description

Patients who fulfill the international definition of unknown primary tumors can be included, except:

  • Young men (\<55 years) with growing mid-line tumors where a germ cell tumor could be expected will not be included.
  • Patients with lymph-node metastases with squamous cell carcinoma in the head and neck region will not be included.
  • Women with adenocarcinoma in lymph nodes in the axilla will not be included.
02

Conditions studied

  • Unknown Primary Tumor

Keywords

  • Unknown primary tumor
  • PET-CT
03

In context

Neoplasms, Unknown Primary

104 studies on the registry are indexed under Neoplasms, Unknown Primary; 18 are open to participants now.

This study's enrollment of 136 is close to the median of 128 across 22 observational studies indexed under Neoplasms, Unknown Primary.

Browse Neoplasms, Unknown Primary studies →

Lead sponsor

Rigshospitalet, Denmark is the lead sponsor of 1,017 studies on the registry; 183 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with unknown tumors

Inclusion criteria

  • Unknown primary tumors

Exclusion criteria

Exclusion Criteria:

  • Young men (\<55 years) with growing mid-line tumors where a germ cell tumor could be expected will not be included.
  • Patients with lymph-node metastases with squamous cell carcinoma in the head and neck region will not be included
  • Women with adenocarcinoma in lymph nodes in the axilla will not be included
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
136 participants (actual)

Interventions

  • ProcedurePET-CT

    no drugs included

06

Study locations

1 site
  • Rigshospitalet
    Copenhagen, 2100, Denmark
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 22, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00269373
Lead sponsor
Rigshospitalet, Denmark
Responsible party
Gedske Daugaard (Associate professor, Rigshospitalet, Denmark) — Principal investigator
First posted
Dec 23, 2005
Start date
Dec 2005
Primary completion
Feb 2012
Completion
Feb 2012
Last update
Feb 22, 2012

Study contacts

Gedske Daugaard
principal investigator · Rigshospitalet, Denmark

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion